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A B S T R A C T
Objectives: To determine the proportion of rifampicin-resistant tuberculosis (RR-TB) patients who
accessed second-line drug susceptibility testing (SL-DST) results following introduction of the Hain
technology in southern provinces, Zimbabwe.
Design: Cohort study using secondary data.
Results: Xpert MTB/RIF results were used to identify 133 RR-TB patients for this study. Their mean age (SD)
was 37.9 (11.1) years, 83 (62%) were males and 106 (80%) were HIV-infected. There were 6 (5%)
participants who had pre-treatment attrition. Of the 133 pulmonary TB (PTB) patients, 117 (80%) had
additional sputum specimens collected; 96 (72%) specimens reached the National TB Reference
Laboratory (NTBRL); 95 (71%) were processed; 68 (51%) had SL-DST results. Only 53 (40%) SL-DST results
reached the peripheral facilities. Median time from specimen reception at the NTBRL to SL-DSTs was 40
days, interquartile range (IQR: 28–67). Median time from presumptive diagn7osis of RR-TB by health care
worker to SL-DST results was 50 days (IQR: 39–80), and increased to 79 days (IQR: 39–101) in facilities
>250 km from the NTBRL. The proportion with any ﬂuoroquinolone resistance was 9 (13.2%).
Conclusion: Although RR-TB patients with PTB were initiated timely on treatment, access to SL-DSTs by
facilities needs improvement. Health inequities exist as remote areas are less likely to get SL-DST results
in time.
© 2019 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
Introduction
Zimbabwe introduced new tuberculosis (TB) management
guidelines in December 2016. The thrust of the guidelines is to
detect TB cases early and to improve access to drug susceptibility
testing (DST) (Ministry of Health and Child Care, 2016). Early
detection of TB patients has been enhanced by increasing both
speed and sensitivity of TB screening and diagnostic methods. This
was not possible with previous methods (mycobacterial culture
and smear microscopy). The former is slow while the latter is less
sensitive for diagnosing TB, especially in pauci-bacillary disease
such as found in children and people living with HIV (PLHIV). The
rate of HIV/TB co-infection in Zimbabwe was around 68% in 2016
(World Health Organisation, 2016).
The new guidelines ushered in a new TB diagnostic algorithm –
a giant leap towards universal access to DST. First, Xpert MTB/RIF1
technology (Cepheid, Sunnyvale, CA, USA) replaced smear micros-
copy as the initial diagnostic test for TB. Second, in case of
rifampicin resistant TB (RR-TB) detected on Xpert MTB/RIF, the
Hain1 line-probe assay (LPA) (Nehren, LifeSciences, Germany)
took precedence as a conﬁrmatory test in addition to culture and
DST (CDST) and furthermore assesses resistance to isoniazid and
second-line drugs (SLD).
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The recommended laboratory turnaround time for Xpert
MTB/RIF is 48 h while that for the Hain LPA is three weeks,
which accounts for culture growth, when required. However,
Hain LPA may be carried out on acid fast-bacilli sputum
positive deposits, thus offsetting the need for preliminary
culture, and this expedites the time to diagnosis. Moreover,
molecular tests are speciﬁc for Mycobacterium tuberculosis
(MTB), even in cultures contaminated by commensals. Thus,
notwithstanding contamination, patients may not be asked to
submit new sputum samples.
Faster diagnostic tests may not be the sine qua non for
favourable treatment outcomes, which are dependent on patients
having started treatment. Studies have shown that faster diagnosis
associated with molecular testing as compared to phenotypic
methods may not translate to favourable treatment outcomes if
patients are not initiated on appropriate treatment early (Nair
et al., 2016). High rates of pre-treatment attrition have been
observed in India and Zimbabwe when molecular and phenotypic
tests were used (Charambira et al., 2016; Nair et al., 2016; Shewade
et al., 2015; Singla et al., 2014). Prior to the introduction of Hain LPA
in Zimbabwe, 44% of RR-TB patients had pre-treatment attrition
while 67% of those started on treatment were initiated on
treatment within two weeks of diagnosis (Charambira et al.,
2016). Pre-treatment attrition may result in community transmis-
sion of RR-TB and poor health outcomes, and this is exacerbated by
the low proportion of RR-TB patients who accessed DST results for
isoniazid and SLD. Without SL-DST results, it is impossible to know
whether there is resistance to ﬂuoroquinolones (FQ) and/or
second-line injectable (SLI) agents and thus to be able to switch
patients to individualised treatment.
Zimbabwe subscribes to the World Health Organization’s
(WHO) End TB strategy of reducing TB incidence by 90% by
2035. A key component of the ﬁrst pillar of the End TB Strategy is
early diagnosis of TB, including universal access to DST (STOP TB
Partnership, 2015). Thus, timely and accurate SL-DST results are
crucial to inform clinical decision making on individualised
treatment among RR-TB patients. Early initiation of RR-TB patients
on appropriate TB medicines reduces mortality and community
transmission of TB (Lönnroth et al., 2013).
The TB diagnostic algorithm has changed since the last study
when DSTs were done using phenotypic methods. The introduction
of Hain LPA could be a game changer in improving diagnosis and
treatment of RR-TB in Zimbabwe as patients with this type of TB
may have multidrug-resistant TB (MDR-TB–deﬁned as resistance
to at least isoniazid and rifampicin) (World Health Organisation,
2017) or extensively drug-resistant TB (XDR-TB, deﬁned as MDR-TB
with added resistance to FQs and SLIs). MDR-TB and XDR-TB are
more expensive and difﬁcult to treat than drug sensitive TB. The
burden of FQ resistance was 10.4% according to the last drug
resistant survey (Ministry of Health and Child Care, 2017). In
neighbouring South Africa, the prevalence of FQ and ethionamide
resistance was 13% (95% CI: 5.0–21.0) and 44.7% (95% CI: 25.8–
63.9), respectively (National Institute for Communicable Diseases,
2014). There is no information in Zimbabwe about access to SL-DST
results after introduction of the Hain LPA.
The aim of this study was to determine among patients
diagnosed with RR-TB on Xpert MTB/RIF assays in the southern
region of Zimbabwe, the number, proportion and associated
clinical and temporal characteristics of those who had SL-DSTs.
Methods
Study design
A cohort study using secondary data.
General setting
Zimbabwe is among the 14 countries globally with a triple-
burden of TB, TB/HIV and MDR-TB (World Health Organisation,
2017). The country is divided into northern and southern regions.
Each region comprises ﬁve provinces and is served by a National
Reference Laboratory. The southern provinces have the highest
burden of human immunodeﬁciency virus (HIV) and TB and they
share borders with South Africa and Botswana (Columbia
University, 2016). Xpert MTB/RIF technology was introduced to
Zimbabwe in 2011 while Hain-LPA (both ﬁrst-line and second-line)
was introduced at the NTBRL in December 2015, exactly a year
before the introduction of the new TB guidelines.
Speciﬁc setting
We focused our study on the southern provinces since there were
no interruptions in Hain-LPA testing at the National Tuberculosis
Reference Laboratory (NTBRL), the laboratory which services the ﬁve
southern provinces. Xpert MTB/RIF testing was decentralised to
district and rural health facilities to improve access to DST, and all
presumptive TB patients are required to produce a sputum specimen
for Xpert testing. If RR-TB is detected, a second specimen is collected
and sent to the NTBRL for Hain SL-LPA and CDST.
Specimen referral to the NTBRL
About 5 mL sputum is collected in screw-capped containers which
are triple-packaged in zip-lock bags and cold-chain maintained using
dry-ice packs before transportation to district laboratories by
motorbikes from Medecins Sans Frontieres; TB CARE1; Ministry of
Health’s and SWIFT, a private courier. From district laboratories,
specimens are sent to the NTBRL using public transportation systems.
In Bulawayo Metropolitan province where the NTBRL is located,
specimens are transported by TB CARE1 directly to the NTBRL.
NTBRL processes
Details of specimens that reach the NTBRL are logged into the
Laboratory Information Management System (LIMS) which assigns
a unique number, the date and time of receipt and the tests that are
ordered. All specimens are decontaminated using sodium hydrox-
ide to kill commensal bacteria. The resultant sputum pellet is
inoculated onto both Lowenstein-Jensen (LJ) agar and MGIT-960
liquid media before they are incubated for growth. All pure
growths of MTB are sub-cultured and DSTs are carried out on LJ and
MGIT 960 media using the proportion method (Salman and Rusch-
Gerdes, 2006; Stop TB Partnership, 2014). The performance of the
NTBRL as measured by the results from external quality assurance
programmes has hitherto been excellent.
Hain second-line LPA testing at the NTBRL
Hain SL-LPA is done using the Genotype MTBDRsl v2.0 (Hain
LifeSciences, GmbH), a WHO-approved test for the detection of
MTB complex and mutations that confer resistance to FQ and SLIs.
The recommended specimens are smear-positive sputum deposits
and solid or liquid culture growths. The paper-based results are
printed and sent to requesting facilities using various transport
systems such as motorbikes and facility ambulances. Since Hain
does not give resistance patterns to individual FQ or SLIs,
phenotypic CDST provides complementary results (Figure 1).
Zimbabwe has a decentralised model of care for MDR-TB
treatment. All RR-TB patients are initiated on standard treatment
regimenscomprising6–8months-longintensivephaseonkanamycin,
levoﬂoxacin, cycloserine, ethionamide and Pyrazinamide, followed by
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14 months-long continuation phase on levoﬂoxacin, cycloserine,
ethionamide and Pyrazinamide. Pyridoxine is given to prevent
neurological adverse events due to cycloserine. The intensive phase
is administered either in hospital or at home and is directly observed,
whilethecontinuationphaseisadministeredfromhome.OnceSL-DST
results are received from the NTBRL, patients with resistance to any of
the drugs are switched to individualised treatment.
Study population
All pulmonary TB patients diagnosed with RR-TB on the Xpert
MTB/RIF between April 2017 and August 2018 in the southern
provinces, Zimbabwe.
Sampling strategy and study procedure
Cluster sampling was used to select the study health facilities
based on the TB notiﬁcations for the year 2016 for each health facility.
First, a list of health facilities (clusters) and their corresponding
notiﬁcations was compiled in MS Excel. Second, health facilities that
notiﬁed <10 patients in 2016 were removed from the list and
cumulative notiﬁcations were compiledfromthe remainingclusters.
Third, probabilityproportional to sizesampling was done to select 30
clusters using a deﬁned starting point and sampling interval. All RR-
TB patients in each cluster were included in the study
Data variables, sources of data and data collection
The following variables were collected: patient name; site name;
district; province; age, sex; HIV status; distance to NTBRL; ART
status; history of TB; date presumed of RR-TB by HCWs; treatment
initiation status; resistance to FQs (genotypic or phenotypic); dates
of (specimen collection; specimen receipt by NTBRL; Xpert testing;
initiation on MDR-TB treatment); SL-DST results; FL-DST results).
Googlemaps were usedto calculate distance to the NTBRL. Datawere
collected by data collectors and the principal investigator using a
structured proforma from August–October 2018. Datawere obtained
from facility laboratory registers. Patient names and age were
documented to ease tracking of patients in presumptive TB registers,
TB treatment registers and LIMS at the NTBRL
Figure 1. The simpliﬁed new TB testing algorithm for Zimbabwe, 2016–18.
BMI = Body mass index; CXR = Chest X-ray; R = rifampicin; H = isoniazid; Z = pyrazinamide; E = ethambutol; MTB = Mycobacteria Tuberculosis; CDST = Culture and drug
susceptibility testing; FL = First line; SL-LPA = second line Line probe assay.
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Analyses and statistics
Data were double-entered in EpiData (v4.0.1.44) and were
analysed using EpiData v2.2.2.186 (EpiData Association, Odense,
Denmark). Medians were calculated if data were not normally
distributed, otherwise means were calculated. Frequencies were
run to calculate the proportion of patients that accessed SL-DST
results or were never initiated on treatment. The chi-square test
was used to measure the association between demographic and
clinical factors and having a SL-DST done at NTBRL. Levels of
signiﬁcance were set at 5%.
Ethics
Ethics approval was obtained from the Ethics Advisory Group,
International Union Against Tuberculosis and Lung Disease (The
Union), (EAG-15/18) and the Medical Research Council of
Zimbabwe (MRCZ/E/201).
Results
The socio-demographic and clinical characteristics of the 133
RR-TB participants are shown in Table 1. Males comprised 83(62%)
of the study population. The mean age (SD) was 37.9 (11.1) years.
The numbers of PLHIV were 106 (80%), and of these, 91% were on
antiretroviral therapy. There were 47(35%) participants with
previous histories of TB. Matebeleland South and Bulawayo
metropolitan provinces had the highest proportions of participants
at 26% and 33% respectively.
Time to treatment initiation is shown in Table 2. The median
time from RR-TB diagnosis to treatment initiation was one day
(IQR: 0–3). A total of 127 (95%) (95% CI: 90.5–97.9) RR-TB patients
were initiated on the standard MDR-TB regimen, of whom 116
(91%) were initiated within one week of diagnosis. There were six 6
(5%) (95% CI: 2.1–9.5) who had pre-treatment attrition, and death
accounted for ﬁve of these patients.
Table 3 shows the characteristics of participants who had SL-
DST results at the NTBRL. Of the 133 participants, 68(51%) had a SL-
DST done at the NTBRL. At univariate analysis, neither sex nor age
nor HIV status were associated with having a SL-DST done. Patients
with a previous history of TB were 77% more likely to have a SL-DST
done compared with those newly diagnosed, P = 0.02; while
facilities located <50 km away from the NTBRL were 61% more
likely to have SL-DSTs done at the NTBRL than those >250 km away,
P = 0.03.
The cascade of care shows that of the 133 participants, 117 (88%)
(95% CI: 81.4–92.5) had sputum collected; 96 (72%) of the
specimens reached the NTBRL; 95 (71%) specimens were processed
and 68 (51%) of the specimens had SL-DST results. Only 53 (40%)
results reached the peripheral facilities (Figure 2).
Table 4 shows the drug-resistance patterns of the specimens. Of
the 68 SL-DST results produced by the NTBRL, 59 (87%) were
sensitive to both FQ and SLIs. The proportion with any FQ
resistance was 9 (13%) (95% CI: 7.1–23.3).
The median time taken from presumption of RR-TB to SL-DST
results at the NTBRL was 50 days (IQR: 39–79.8). The time taken
increased to 79 days (IQR: 39–101) in facilities that were >250 km
away from the NTBRL (Table 5).
There were 71 RR-TB patients with FL-DST results. Of these, 35
(49%) had rifampicin mono-resistance, and RR-TB was not
conﬁrmed by in 4(6%) patients. There were 32 MDR-TB patients,
and 11 of them had low-level isoniazid resistance.
Discussion
This is the ﬁrst study to determine access to SL-DST among RR-
TB patients following introduction of the Hain LPA in southern
Zimbabwe. The study has some interesting ﬁndings.
First, the intervals from presumption of RR-TB to diagnosis and
treatment initiation were short, and within targeted timelines.
Only 10(9%) patients experienced treatment delays of >7 days.
Most importantly, 95% of the RR-TB participants were initiated on
standard MDR-TB treatment which is a higher proportion of
treatment initiation compared with previous studies in northern
Zimbabwe and India (Charambira et al., 2016; Kant et al., 2017) but
was consistent with the ﬁndings from some parts of India
(Shewade et al., 2018). This could be attributed to decentralisation
of both Xpert MTB/RIF testing and MDR-TB treatment in
Zimbabwe. Pre-treatment attrition in this study was consistent
with other ﬁndings from Africa and India (MacPherson et al., 2014;
Shewade et al., 2018), and was mainly due to deaths. It was,
Table 1
Socio-demographic and clinical characteristics of patients diagnosed with
rifampicin resistant tuberculosis on Xpert MTB/RIF in southern provinces of
Zimbabwe, April 2017–August 2018.
Variable Number (%)
Total 133
Sex:
Male 83 (62)
Female 50 (38)
Age category in years:
<25 13 (10)
25–34 39 (29)
35–44 54 (41)
45–54 14 (11)
55–64 8 (6)
65+ 3 (2)
Missing age 2 (1)
Type of TB patient:
New 83 (63)
Retreatment 47 (35)
Not recorded 2 (2)
Treatment status:
Initiated 127 (95)
Not initiated 6 (5)
 Died 5 (83)
 LFU 1 (17)
HIV status:
Negative 26 (20)
Positive 106 (80)
Not recorded 1 (<1)
Province:
Matebeleland South 35 (26)
Matebeleland North 16 (12)
Bulawayo Metropolitan 44 (33)
Midlands 21 (16)
Masvingo 17 (13)
Distance from NTBRL (km):
<50 43 (32)
50–250 53 (40)
>250 37 (28)
Median (IQR) 155 (12–274)
SD = Standard deviation; NTBRL = National Tuberculosis Reference Laboratory;
IQR = Inter-quartile range; km = Kilometers; LFU = loss to follow-up (attrition).
Table 2
Time to treatment initiation among patients diagnosed with rifampicin resistant TB
on Xpert MTB/RIF in the southern provinces of Zimbabwe, April 2017–August 2018.
Time interval (days) Number initiated on treatment (%)
Total 127
7 116 (91)
8–14 7 (5)
15–21 2 (2)
21–28 1 (1)
Missing data 1 (1)
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Table 3
Socio-demographic and clinical characteristics associated with having second line drug susceptibility testing among patients diagnosed with rifampicin resistance on Xpert
MTB/RIF in the southern provinces of Zimbabwe, April 2017–August 2018.
Variable Total Number who had SL-DST results (%)† RR 95% CI P-value
Total 133 68 (51)
Sex
Male 83 44 (53) 1.08 (0.83–1.41) 0.57
Female 50 24 (48) 1.00
Age in years
<25 13 6 (46) 1.00
25–34 39 20 (51) 1.05 (0.77–1.44) 0.75
35–44 54 33 (61) 1.13 (0.88–1.45) 0.33
45–54 14 5 (36) 0.81 (0.37–1.76) 0.58
55–64 8 3 (38) 0.80 (0.26–2.50) 0.70
65+ 3 1 (33) 0.64 (0.10–5.13) 0.69
Missing age 3 0 (0) – –
Type of TB patient
New 83 37 (45) 1.00
Retreatment 47 31 (66) 1.77 (1.08–2.90) 0.02
Not recorded 3 0 (0) – –
HIV status
Negative 26 15 (58) 1.00
Positive 106 52 (49) 0.93 (0.79–1.11) 0.43
Not recorded 1 1 (100) –
Province
Matebeleland South 35 19 (54) 0.85 (0.52–1.39 0.53
Matebeleland North 16 8 (50) 0.71 (0.31–1.64) 0.43
Bulawayo Metropolitan 44 27 (61) 1.00
Midlands 21 9 (43) 0.60 (0.30–1.23) 0.16
Masvingo 17 5 (29) 0.38 (0.15–0.94) 0.03
Distance to NTBRL (km)
<50 43 27 (63) 1.61 (1.04–2.48) 0.03
50–250 53 27 (51) 1.24 (0.90–1.75) 0.22
250 37 14 (38) 1.00 –
RR = Relative risk; SL-DST = Second line drug susceptibility test; NTBRL = National Tuberculosis Reference Laboratory; CI = Conﬁdence interval; TB = Tuberculosis;† = row
percentages.
Figure 2. Cascade of care from diagnosis of RR-TB to reception of second line DST results at peripheral facilities among patients diagnosed with rifampicin resistant TB on
Xpert MTB/RIF in the southern provinces of Zimbabwe, April 2017–August 2018.
a,b,c,d,e = denominator for calculations is 133 RR-TB patients diagnosed with RR-TB on Xpert MTB/RIF assay
z = only one specimen was received per patient; † = Losses were due to no growth on culture; poor documentation on laboratory request forms regarding tests to be done
(diagnosis/follow up). Follow up tests are for disease prognosis, and only need culture. NBTRL = National Tuberculosis Reference Laboratory; RR-TB = rifampicin resistant TB;
SL-DST = Second-line drug susceptibility testing.
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however, lower than the 10.3% reported among drug-susceptible
TB patients in Bulawayo Metropolitan province (Mugauri et al.,
2018).
Second, there were huge leakages in SL-DST results produced at
the NTBRL compared with those received by peripheral facilities.
This ﬁnding is consistent with ﬁndings from South Africa (Jacobson
et al., 2017). Reasons for leakages could be attributed to challenges
in transporting the paper-based laboratory results to health
facilities. Leakages in pre-NTBRL processes may be due to failure
to collect sputum specimens for SL-DST as reported elsewhere
(Murongazvombo et al., 2018). Even when sputum specimens are
collected, some do not reach the NTBRL owing to specimen
transportation challenges. Within the NTBRL, specimen leakages
may stem from culture no growths and culture contaminations as
described in a previous study (Timire et al., 2018a,b). No growths
are likely to be common among specimens that have long transit
times to the NTBRL since MTB may lose viability. Lack of sufﬁcient
clinical data on request forms on the type of test to be done
(diagnostic or treatment monitoring tests) may result in some
specimens getting culture results and not SL-DSTs. Culture is done
routinely to monitor MDR-TB treatment.
Third, the cascade of care of RR-TB patients may be a tracer for
quality of care they receive. The proportion of patients with SL-DST
done at the NTBRL was inversely proportional to distance from the
NTBRL. Facilities >250 km away from the NTBRL are mostly in
remote areas with poor road networks leading to logistical
challenges in getting specimens to the NTBRL. Even if the
specimens ﬁnally reach the NTBRL, the MTB may have lost
viability. Challenges with processes of sputum specimen transpor-
tation to NRLs have been reported in other countries (Kilale et al.,
2013; Qi et al., 2011).
Increased access to SL-DST among previously treated patients
could be attributed to adherence to guidelines on sputum
specimen collection for SL-DST by HCWs for this group of patients.
Previously treated TB is a known risk factor for RR-TB, and even
before the introduction of new guidelines CDST was prioritised for
this group.
The high proportion of RR-TB patients initiated on treatment in
this study means that most patients were enrolled into care, and
had high chances of providing a sputum specimen for SL-DST. The
converse is true for a high pre-treatment attrition. However, the
consequences of starting the standard MDR-TB regimen (with FQ
and SLIs as backbone agents) early meant that about 13% of
patients with undetected FQ resistance were potentially exposed
to sub-optimal treatments. This ﬁgure is comparable to the
proportion of FQ resistance (10%) among RR-TB patients in
Zimbabwe (Ministry of Health and Child Care, 2017), but was
remarkably lower than the proportion of patients who were
started on suboptimal therapies in South Africa and China
(Jacobson et al., 2017; Chen et al., 2016). Suboptimal therapies
are a wastage of drugs; lead to poor treatment outcomes; expose
patients to toxicities and increase risk of acquisition of further drug
resistance, and ongoing community transmission of DR-TB strains
(Chen et al., 2016; Kendall et al., 2017). The proportion of
participants who were started on a suboptimal therapy may be
higher if low-level isoniazid resistance is taken into account: at
least 11 of the 32 participants diagnosed with MDR-TB had low-
Table 4
Drug-resistance patterns among patents diagnoses with rifampicin resistant
tuberculosis, by treatment history and demographic factors, April 2017–August
2018, Zimbabwe.
Variables Sensitive to all the SLD Any FQz resistance
n (%) n (%)
Total 68 59 (87) 9 (13)
Sex
Male 44 40 (91) 4 (9)
Female 24 19 (79) 5 (21)
Age category
<25 6 5 (83) 1 (17)
25–34 20 18 (90) 2 (10)
35–44 33 27 (82) 6 (18)
45–54 5 5 (100) 0 (0)
55–64 3 3 (100) 0 (0)
>65 1 1 (100) 0 (0)
Type of TB patient
New 37 32 (86) 5 (14)
Retreatment 31 27 (87) 4 (13)
Treatment status
Initiated 65 58 (89) 7 (11)
Not initiated 3 1 (33) 2 (67)
HIV status
Positive 52 43 (83) 9 (17)
Negative 15 15 (100) 0 (0)
Not recorded 1 1 (100) 0 (0)
Province
Matebeleland South 19 15 (79) 4 (21)
Matebeleland North 8 7 (88) 1 (12)
Bulawayo Metropolitan 27 25 (93) 2 (7)
Midlands 9 8 (89) 1 (11)
Masvingo 5 4 (80) 1 (20)
SLD = second-line drugs; FQ = Fluoroquinolone; XDR-TB = extensively drug-resistant
tuberculosis; R = Rifampicin; H = Isoniazid. z = Only 5(7%) had FQ mono-resistance
while 4(6%) had extensively drug-resistant TB (XDR-TB).
Table 5
Time taken in days among patients diagnosed with RR-TB on Xpert MTB/RIF (April 2017–August 2018), Zimbabwe.
Presumption to
RR-TB diagnosis
Specimen collection to receipt by NTBRL Specimen receipt by NTBRL to SL-DST result Overall delay in SL-DST resultz
Variable Median IQR Median IQR Median IQR Median IQR
All patients 1 0–1 8 4–19.3 40 28–67 50 39–79.8
Type of TB patient
New 1 0–1 8.5 5–27.3 38.5 27.3–67.8 50 38.3–78
Retreatment 1 0–1 6.5 3.3–19.0 41.5 28.5–66.3 58 39.3–83.8
Not recorded 1.5 0–1.5 – – – – – –
Distance to NTBRL
<50 km 1 1–3 5 2–11 41 27–67 49 36–73.5
50–250 km 0 0–1 7 4–19 38 24–53 50 40.8–73.5
250 km 1 0–1 18 8–30.8 46 28–76 79 39–101
RR-TB = Rifampicin resistant tuberculosis; SL-DST = second line drug susceptibility test; IQR = Interquartile range; NTBRL = National Tuberculosis Reference Laboratory;
FQ = Fluoroquinolone; XDR-TB = extensively drug resistant tuberculosis. z deﬁned here as time from presumption of RR-TB to the date when a SL-DST was produced by the
NTBRL.
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level isoniazid resistance. Cross resistance between low-level
isoniazid resistance and ethionamide resistance, one of the drugs
in the standard MDR-TB regimen has been reported (Bollela et al.,
2016; Qamar et al., 2017).
The median time to SL-DSTs was comparable to results obtained
in South Africa but was much shorter than in China (Jacobson et al.,
2017; Chen et al., 2016). Delayed access to SL-DST implies that
some patients on the standard MDR-TB regimen, especially those
in facilities >250 km from the NTBRL may receive suboptimal
therapies for longer periods. These patients, if they get SL-DST
results at all, may get switched to effective, individualised
regimens after 79 days – the overall delay in SL-DST results!
Rapid diagnosis, early and regulated treatment on effective MDR-
TB drugs is key for RR-TB control efforts (Chen et al., 2016). Early
access to SL-DSTs is indispensable, as it informs better clinical
decisions regarding the number and choice of effective drugs in the
regimen, usually a mix of 4 drugs during the intensive phase and
3 drugs during the continuation phase (Ahuja et al., 2012; Kendall
et al., 2017).
Several programmatic implications arise from this study. The
NTP should ensure both increased speed and access to SL-DSTs
through strengthening sputum transportation; relay of results
back to requesting facilities and ensuring adherence to national
guidelines on sputum collection and referral. Post-NTBRL
leakages in SL-DST results may be reduced if the NTP introduces
electronic reporting to increase both speed and access to SL-DST
results by health facilities. Short message services (SMSs) have
improved result turn-around times in early infant diagnosis as
compared to courier-based reporting (Vojnov et al., 2017). The
NTP may also consider investing in point-of-care diagnostics that
offer sensitivity patterns to FQ and SLIs even in peripheral areas to
ensure equity of access to SL-DSTs (Xie et al., 2017). Electronic
tracking of specimens referred for SL-LPA is also recommended, a
lack of which was a barrier to accessing SL-DSTs in India (Shewade
et al., 2015).
Low-level isoniazid resistance may predict ethionamide resis-
tance. In Pakistan, 26.6% of low-level isoniazid resistant MTB
strains were conﬁrmed to have ethionamide resistance (Qamar
et al., 2017). Zimbabwe’s current guidelines are silent on this, and
FL-DST reporting templates may need to be updated in order to
capture low-level isoniazid resistance.
The high proportion of PLHIV among RR-TB patients poses a
diagnostic dilemma; PLHIV produce pauci-bacillary specimens,
and without preliminary culture, weak bands are produced which
cannot be interpreted. The full beneﬁts of LPA, like shortened SL-
DST result turn-around time may not be realised in HIV-burdened
settings since LPA can only be carried out on smear-positive
sputum deposits.
Pre-treatment attrition mainly due to death implies delayed
health seeking behaviour. Delayed health seeking behaviour
may result in ampliﬁcation of drug resistance and in
community transmission of TB. There is a need to intensify
health promotion messaging on beneﬁts of early health
seeking and to increase active case ﬁnding strategies (contact
tracing and targeted active screening for TB) as per national
guidelines.
The strengths of this study were: the study was done in a
routine programme setting, and the results may be generalisable to
this population. Quality of data was improved by use of different
data sources as we tracked patients from facility registers and
registers at NTBRL as we checked for accuracy (consistency and
completeness) of data. We assessed the overall access to SL-DSTs
regardless of the method used (phenotypic or genotypic). In most
cases the results from the two methods were available with an
excellent concordance. Data collection allowed for laboratory
processes to be completed or at least for the specimens to reach the
NTBRL, especially for those specimens that were collected close to
the end of the collection period. To cater for any anticipated
teething challenges, we collected data for RR-TB which was
diagnosed at least four months after the introduction of Hain
technology. All data were double-entered to minimise data entry
errors.
Our limitations were that we do not know if the patients who
had FQ resistance were switched to individualised regimes as we
did not collect this data. In addition, the overall delay in getting SL-
DSTs was underreported in this study. This is because the delay was
based on a proxy date when SL-DST results were produced by the
NTBRL, instead of the date when results were received by facilities.
The latter dates were poorly documented, with most results yet to
be transcribed from NTBRL forms onto TB registers or patient
treatment booklets.
We could not assess pre-diagnosis attrition as this was not
within the scope of our study. However, studies in Zimbabwe and
India have shown higher proportions of pre-diagnosis attrition
than those of pre-treatment attrition (Shewade et al., 2017;
Murongazvombo et al., 2018). We anticipated that our pre-
treatment attrition was much lower than pre-diagnosis attrition.
Stigma related to TB may result in higher pre-diagnosis attrition
since a positive TB result is viewed as a proxy for HIV positive
status (Craig et al., 2017).
In conclusion, access to SL-DST in Zimbabwe needs improve-
ment. Health inequities exist as patients in peripheral areas are less
likely to get SL-DST results in time. Strengthening specimen
referral and result feedback mechanisms may increase access to
SL-DST results.
Funding
This study was funded by the United Kingdom’s Department for
International Development (DFID); Ministry of Health and Child
Care, Zimbabwe and the World Health Organisation. The funders
had no role in study design, data collection; analysis; preparation
of the manuscript and decision to publish. Collins Timire is a Senior
Operational Research Fellow with the Centre for Operational
Research, International Union Against Tuberculosis and Lung
Disease (The Union), Paris, France.
Author contributions
CT, KCT, AMVK and ADH conceived and designed the study and
all authors read and approved the study protocol; CT and BM
collected the data. CT and KCT analysed the data. CT drafted the
manuscript and all authors critically reviewed the manuscript. All
authors read and approved the ﬁnal manuscript.
Disclosure policy
The authors declare that there is no conﬂict of interest
regarding the publication of this paper.
References
Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN. Multidrug
resistant pulmonary tuberculosis treatment regimens and patient outcomes: an
individual patient data meta-analysis of 9,153 Patients. PLoS Med 2012;9(8)
e1001300.
Bollela VR, Namburete EI, Feliciano CS, Macheque D, Harrison LH, Caminero JA.
Detection of katG and inhA mutations to guide isoniazid and ethionamide use
for drug-resistant tuberculosis. Int J Tuberc Lung Dis 2016;20(8):1099–104, doi:
http://dx.doi.org/10.5588/ijtld.15.0864.
Charambira K, Ade S, Harries AD, Ncube RT, Zishiri C, Sandy C, et al. Diagnosis and
treatment of TB patients with rifampicin resistance detected using Xpert 1
MTB/RIF in Zimbabwe. Public Health Action 2016;6(2):122–8, doi:http://dx.doi.
org/10.5588/pha.16.0005.
242 C. Timire et al. / International Journal of Infectious Diseases 81 (2019) 236–243
Chen Y, Yuan Z, Shen X, Wu J, Wu Z, Xu B. Resistance to second-line antituberculosis
drugs and delay in drug susceptibility testing among multidrug-resistant
tuberculosis patients in Shanghai. BioMed Res Int 2016;2016:, doi:http://dx.doi.
org/10.1155/2016/2628913.
Columbia University. Zimbabwe Population-based HIV Impact Assessment (ZIM-
PHIA) 2015-2016. 2016 Harare, Zimbabwe. Retrieved from http://phia.icap.
columbia.edu/wp-content/uploads/2016/11/ZIMBABWE-Factsheet.FIN_.pdf.
Craiga GM, Daftary A, Engel N, O’Driscoll S, Ioannaki A. Tuberculosis stigma as a
social determinant of health: a systematic mapping review of research in low
incidence countries. International Society for Infectious Diseases 2017;56:90–
100, doi:http://dx.doi.org/10.1016/j.ijid.2016.10.011.
Jacobson KR, Barnard M, Kleinman MB, Streicher EM, Ragan EJ, White LF, et al.
Implications of failure to routinely diagnose resistance to second-line drugs in
patients with rifampicin-resistant tuberculosis on Xpert MTB/RIF: a multisite
observational study. Clin Infect Dis 2017;64(11):1502–8, doi:http://dx.doi.org/
10.1093/cid/cix128.
Kant S, Singh AK, Parmeshwaran GG, Haldar P, Malhotra S, Kaur R. Delay in initiation
of treatment after diagnosis of pulmonary tuberculosis in primary health care
setting: eight year cohort analysis from district Faridabad, Haryana, North India.
Rural Remote Health 2017;17(3):1–8, doi:http://dx.doi.org/10.22605/RRH4158.
Kendall EA, Cohen T, Mitnick CD, Dowdy DW. Second line drug susceptibility testing
to inform the treatment of rifampin-resistant tuberculosis: a quantitative
perspective. Int J Infect Dis 2017;56:185–9, doi:http://dx.doi.org/10.1016/j.
ijid.2016.12.010.
Kilale A, Ngowi B, Mﬁnanga G, Egwagwa S, Doulla B, Kumar A, et al. Are sputum
samples of retreatment tuberculosis reaching the reference laboratories? A 9-
year audit in Tanzania. Public Health Action 2013;I(2):156–9, doi:http://dx.doi.
org/10.5588/pha.12.0103.
Lönnroth K, Corbett E, Golub J, Godfrey-Faussett P, Uplekar M, Weil D, et al.
Systematic screening for active tuberculosis: rationale, deﬁnitions and key
considerations. Int J Tuberc Lung Dis 2013;17(3):289–98, doi:http://dx.doi.org/
10.5588/ijtld.12.0797.
MacPherson P, Houben RM, Glynn JR, Corbett EL, Kranzer K. Pre-treatment loss to
follow-up in tuberculosis patients in low- and lower-middle-income countries
and high-burden countries: a systematic review and meta-analysis. Bull World
Health Organ 2014;92(2):126–38, doi:http://dx.doi.org/10.2471/BLT.13.124800.
Ministry of Health and Child Care. Zimbabwe tuberculosis management guidelines.
2016 Harare, Zimbabwe.
Ministry of Health and Child Care. National Tuberculosis Drug Resistance Survey for
Zimbabwe. 2017 Harare, Zimbabwe.
Mugauri H, Shewade HD, Dlodlo RA, Hove S, Sibanda E. Bacteriologically conﬁrmed
pulmonary tuberculosis patients: loss to follow-up, death and delay before
treatment initiation in Bulawayo, Zimbabwe from 2012–2016. Int J Infect Dis
2018;76:6–13, doi:http://dx.doi.org/10.1016/j.ijid.2018.07.012.
Murongazvombo AS, Dlodlo RA, Shewade HD, Robertson V, Hirao S, Pikira E, et al.
Where, when and how many tuberculosis patients are lost from presumption
until treatment initiation? A step by step assessment in a rural district in
Zimbabwe. Int J Infect Dis 2018;78:113–20, doi:http://dx.doi.org/10.1016/j.
ijid.2018.10.013.
Nair D, Tripathy JP, Navneethapandian P, Harries AD, Klintona JS, Watsona B, et al.
Impact of rapid molecular diagnostic tests on time to treatment initiation and
outcomes in patients with multidrug-resistant tuberculosis, Tamil, Nadu, India.
Trans R Soc Trop Med Hyg 2016;2016(October):1–8, doi:http://dx.doi.org/
10.1093/trstmh/trw060.
National Institute for Communicable Diseases. South African Tuberculosis Drug
Resistance Survey 2012-14. 2014 Pretoria, South Africa.
Qamar S, Farooki J, Jabeen K, Hasan R. Phenotypic low-level isoniazid resistance as a
marker to predict ethionamide resistance in Mycobacterium tuberculosis. Int J
Mycobacteriol 2017;6:167–70, doi:http://dx.doi.org/10.4103/ijmy.ijmy_34_17.
Qi W, Harries AD, Hinderaker S. Performance of culture and drug susceptibility
testing in pulmonary tuberculosis patients in northern China. Int J Tuberc Lung
Dis 2011; 15: 137–139. Int J Tuberc Lung Dis 2011;15:137–9.
Salman S, Rusch-Gerdes S. MGIT Procedure Manual or BACTECTM MGIT 960TM TB
system. 2006.
Shewade HD, Govindarajan S, Sharath B, Tripathy JP, Chinnakali P, Kumar A, et al.
MDR-TB screening in a setting with molecular diagnostic techniques: Who got
tested, who didn’t and why?. Public Health Action 2015;5(2):132–9.
Shewade HD, Nair D, Klinton JS, Parmar M, Lavanya J, Murali L, et al. Low pre-
diagnosis attrition but high pre-treatment attrition among patients with MDR-
TB: an operational research from Chennai, India. J Epidemiol Glob Health 2017;7
(4):227–33, doi:http://dx.doi.org/10.1016/j.jegh.2017.07.001.
Shewade HD, Shringarpure KS, Parmar M, Patel N, Kuriya S, Shihora S, et al. Delay
and attrition before treatment initiation among MDR-TB patients in ﬁve
districts of Gujarat, India. Public Health Action 2018;8(2):59–65, doi:http://dx.
doi.org/10.5588/pha.18.0003.
Singla N, Satyanarayana S, Sachdeva KS, Van den Bergh R, Reid T, Tayler-Smith K,
et al. Impact of introducing the line probe assay on time to treatment initiation
of MDR-TB in Delhi, India. PLoS One 2014;9:e102989.
Stop TB Partnership. Mycobacteriology Laboratory Manual. 2014 Geneva,
Switzerland.
STOP TB Partnership. The paradigm shift 2016-2020: Global plan to End TB. 2015
Geneva, Switzerland.
Timire C, Takarinda KC, Harries AD, Mutunzi H, Manyame-Murwira B, Kumar AMV,
et al. How has the Zimbabwe mycobacterial culture and drug sensitivity testing
system among re-treatment tuberculosis patients functioned during the scale-
up of the Xpert MTB/RIF assay?. Trans R Soc Trop Med Hyg 2018a;112(6):285–
93, doi:http://dx.doi.org/10.1093/trstmh/try054.
Timire C, Takarinda KC, Sandy C, Zishiri C, Kumar AMV, Harries AD. Has TB CARE1
sputum transport improved access to culture services for retreatment
tuberculosis patients in Zimbabwe?. Public Health Action 2018b;8(2):66–71.
Vojnov L, Markby J, Boeke C, Penazzato M, Urick B, Ghadrshenas A, et al. Impact of
SMS/GPRS printers in reducing time to early infant diagnosis compared with
routine result reporting: a systematic review and meta-analysis. J Acquir
Immune Deﬁc Syndr 2017;76(5):522–6, doi:http://dx.doi.org/10.1097/
QAI.0000000000001526.
World Health Organisation. Global TB Report 2016. 2016 Geneva, Switzerland.
Retrieved from WHO/HTM/TB/2016.13.
World Health Organisation. Global Tuberculosis Report 2017. 2017 Geneva,
Switzerland. Retrieved from WHO/HTM/TB/2017.23.
Xie YL, Chakravorty S, Armstrong DT, Hall SL, Via LE, Song T, et al. Evaluation of a
rapid molecular drug-susceptibility test for tuberculosis. N Engl J Med 2017;377
(11):1043–54, doi:http://dx.doi.org/10.1056/NEJMoa1614915.
C. Timire et al. / International Journal of Infectious Diseases 81 (2019) 236–243 243
